GLOBAL BLOOD THERAPEUTICS IN (GBT) Stock Price & Overview
NASDAQ:GBT • US37890U1088
Current stock price
The current stock price of GBT is 68.49 USD. Today GBT is up by 0.01%. In the past month the price increased by 0.9%. In the past year, price increased by 131.39%.
GBT Key Statistics
- Market Cap
- 4.621B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -5.01
- Dividend Yield
- N/A
GBT Stock Performance
GBT Stock Chart
GBT Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to GBT. When comparing the yearly performance of all stocks, GBT is one of the better performing stocks in the market, outperforming 99.73% of all stocks.
GBT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to GBT. While GBT seems to be doing ok healthwise, there are quite some concerns on its profitability.
GBT Earnings
GBT Forecast & Estimates
22 analysts have analysed GBT and the average price target is 67.97 USD. This implies a price decrease of -0.77% is expected in the next year compared to the current price of 68.49.
For the next year, analysts expect an EPS growth of 2.94% and a revenue growth 47.16% for GBT
GBT Groups
Sector & Classification
GBT Financial Highlights
Over the last trailing twelve months GBT reported a non-GAAP Earnings per Share(EPS) of -5.01. The EPS decreased by -16.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -137.3% | ||
| ROA | -37.05% | ||
| ROE | N/A | ||
| Debt/Equity | 4.92 |
GBT Ownership
GBT Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GBT
Company Profile
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. The company is headquartered in South San Francisco, California and currently employs 457 full-time employees. The company went IPO on 2015-08-12. The firm is focused on Oxbryta (voxelotor), which is the Food and Drug Administration (FDA) approved medicine that inhibits sickle hemoglobin (HbS) polymerization, the root cause of red blood cell sickling in sickle cell disease (SCD). The company is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in Phase III development to address pain crises associated with the disease, and GBT021601 (GBT601), the Company’s next-generation HbS polymerization inhibitor. The firm is focused on areas of the United States, Europe, the Gulf Cooperation Council (GCC), region of the Middle East, and Latin America.
Company Info
IPO: 2015-08-12
GLOBAL BLOOD THERAPEUTICS IN
181 Oyster Point Blvd
South San Francisco CALIFORNIA 94080 US
CEO: Ted W. Love
Employees: 457
Phone: 16507417700.0
GLOBAL BLOOD THERAPEUTICS IN / GBT FAQ
What does GBT do?
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. The company is headquartered in South San Francisco, California and currently employs 457 full-time employees. The company went IPO on 2015-08-12. The firm is focused on Oxbryta (voxelotor), which is the Food and Drug Administration (FDA) approved medicine that inhibits sickle hemoglobin (HbS) polymerization, the root cause of red blood cell sickling in sickle cell disease (SCD). The company is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in Phase III development to address pain crises associated with the disease, and GBT021601 (GBT601), the Company’s next-generation HbS polymerization inhibitor. The firm is focused on areas of the United States, Europe, the Gulf Cooperation Council (GCC), region of the Middle East, and Latin America.
What is the stock price of GLOBAL BLOOD THERAPEUTICS IN today?
The current stock price of GBT is 68.49 USD. The price increased by 0.01% in the last trading session.
What is the dividend status of GLOBAL BLOOD THERAPEUTICS IN?
GBT does not pay a dividend.
What is the ChartMill technical and fundamental rating of GBT stock?
GBT has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Should I buy GBT stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on GBT.
Is GLOBAL BLOOD THERAPEUTICS IN (GBT) expected to grow?
The Revenue of GLOBAL BLOOD THERAPEUTICS IN (GBT) is expected to grow by 47.16% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.